RegulatoryJul 17, 2026, 07:34 AM
Clearmind Notes Key Regulatory Support for Neuropsychiatric Treatments
AI Summary
Clearmind Medicine highlighted significant regulatory and inter-agency developments this week, which support the advancement of innovative treatments for serious neuropsychiatric and addiction disorders. These developments include final FDA guidance on psychedelic clinical investigations and new collaborative initiatives involving multiple U.S. government health agencies. The company's CEO, Dr. Adi Zuloff-Shani, emphasized the importance of expanding treatment options for underserved patient populations.
Key Highlights
- Clearmind noted significant regulatory and inter-agency developments.
- Developments support innovative treatments for neuropsychiatric and addiction disorders.
- FDA issued final guidance on psychedelic clinical investigations.
- Public hearing planned on therapeutic use of psychedelics.
- New MoUs and initiatives involve HHS, VA, FDA, NIDA, ARPA-H, HRSA.
- Clearmind's CMND-100 is in FDA-cleared Phase I/IIa trials for AUD.
- Trials for CMND-100 are conducted at Yale and Johns Hopkins.
- Company holds 19 patent families, including 32 granted patents.
Price Impact
More from CMND